2013-11-14T09:58:59-06:00 2012-12-31 410746749 CLIFTONLARSONALLEN LLP 4250 N FAIRFAX DRIVE SUITE 1020 ARLINGTON VA 22203 990 2012-01-01 521224577 BIOTECHNOLOGY INDUSTRY ORGANIZATION BIOT 2029629200 1201 MARYLAND AVENUE SW NO 900 WASHINGTON DC 20024 JOANNE M DUNCAN 2029629200 2013-11-11 1 KAREN GRIES P00078514 5712279500 2012 2016-02-24 21:20:13Z JAMES C GREENWOOD 1201 MARYLAND AVENUE SW NO 900 WASHINGTON DC 20024 96516207 0 X WWW.BIO.ORG X 1993 DC THE BIOTECHNOLOGY INDUSTRY ORGANIZATION (BIO) MISSION IS TO SUPPORT THE BIOTECHNOLOGY INDUSTRY TO EXPAND THE BOUNDARIES OF SCIENCE TO BENEFIT MANKIND BY PROVIDING BETTER HEALTH CARE, ENHANCED AGRICULTURE AND A CLEANER AND SAFER ENVIRONMENT. IT IS BIO'S MISSION TO BE THE CHAMPION OF BIOTECHNOLOGY AND THE ADVOCATE OF OUR MEMBER ORGANIZATIONS BOTH LARGE AND SMALL. 116 116 184 196 338892 -11938 0 0 59284196 59883011 1994532 2400453 3900 3959 61282628 62287423 0 232395 0 0 25311029 27075315 0 0 0 35650393 37619628 60961422 64927338 321206 -2639915 65857637 65054922 27777267 26151093 38080370 38903829 X THE BIOTECHNOLOGY INDUSTRY ORGANIZATION (BIO) REPRESENTS MORE THAN 1,100 COMPANIES AND ORGANIZATIONS IN WASHINGTON DC, STATE CAPITALS, AND INTERNATIONAL FORA. BIO IS FOUNDED ON THE PRINCIPLE THAT POLICY MUST NURTURE INNOVATION IN THE LIFE SCIENCES TO OVERCOME CHALLENGES IN HEALTH CARE, AGRICULTURE, INDUSTRY, AND THE ENVIRONMENT. OUR MEMBERS REPRESENT COMPANIES OFFERING A SPECTRUM OF BIOTECHNOLOGY APPLICATIONS ACROSS MAJOR SECTORS OF THE ECONOMY. BIO MEMBERS ALSO INCLUDE UNIVERSITIES, NONPROFITS, PATIENT GROUPS, AND OTHER ORGANIZATIONS THAT PLAY AN IMPORTANT ROLE IN THE FUTURE OF THE LIFE SCIENCES. BIO'S ACTIVITIES ARE BROKEN DOWN INTO TWO PROGRAMS - ADVOCACY AND SERVICES. 0 0 ADVOCACYBIO'S ADVOCACY EFFORTS REFLECT THE PRIORITIES IDENTIFIED BY THE BIO BOARD OF DIRECTORS AND THE FOUR SECTION GOVERNING BOARDS.THE BOARD OF DIRECTORS FOCUSES ON ISSUES OF IMPORTANCE TO ALL BIO MEMBERS, REGARDLESS OF THEIR SIZE OR TECHNOLOGY. THESE CROSS-CUTTING ADVOCACY ACCOMPLISHMENTS IN 2012 ARE LISTED BELOW. SAFEGUARDED AND ADVANCED INTELLECTUAL PROPERTY PROTECTIONS, DOMESTICALLY AND INTERNATIONALLY. FOSTERED A DIALOGUE ABOUT ETHICS AND PROACTIVELY ADVANCED THE SOCIALLY RESPONSIBLE USE OF BIOTECHNOLOGY. PROMOTED INVESTMENT IN GOVERNMENT AND ACADEMIC RESEARCH. INITIATED EFFORTS TO COMPREHENSIVELY REFORM THE U.S. TAX CODE TO PROMOTE INNOVATION AND INVESTMENT IN BIOTECHNOLOGY. EXPANDED OUTREACH TO FOREIGN GOVERNMENTS AND INTERNATIONAL ENTITIES TO EDUCATE ON POLICY ISSUES OF IMPORTANCE TO THE BIOTECHNOLOGY INDUSTRY AND TO IMPROVE THE INVESTMENT AND REGULATORY CLIMATE FOR BIOTECH PRODUCTS.THE HEALTH SECTION 2012 ACCOMPLISHMENTS: INFLUENCED IMPROVEMENTS TO THE U.S. FOOD AND DRUG ADMINISTRATION'S (FDA'S) PROCESS FOR HUMAN DRUG REVIEW. ENHANCED PATIENT ACCESS TO INNOVATIVE THERAPIES. ADVOCATED FOR BIOSIMILARS POLICIES THAT PROTECT PATIENT SAFETY AND PROMOTE BIOMEDICAL INNOVATION. PROMOTED DEVELOPMENT AND USE OF RESEARCH TOOLS, MOLECULAR DIAGNOSTICS AND PERSONALIZED THERAPIES. ADVOCATED FOR POLICIES THAT FOSTER VACCINE INNOVATION AND PROMOTE PANDEMIC AND BIO-DEFENSE PREPAREDNESS. INFLUENCED IMPROVEMENTS TO THE INTERNATIONAL ENVIRONMENT FOR BIOMEDICAL INNOVATION.THE EMERGING COMPANIES SECTION 2012 ADVOCACY ACCOMPLISHMENTS: ADVANCED THE INTEREST OF EMERGING COMPANIES IN CAPITAL FORMATION AND FINANCIAL SERVICES POLICY. INCREASED OPPORTUNITIES FOR SMALL COMPANIES TO RECEIVE FEDERAL GRANTS. ADVOCATED FOR TAX POLICIES SUPPORTING INNOVATIVE EMERGING COMPANIES. ADVOCATED FOR THE REMOVAL OF BURDENSOME FINANCIAL REPORTING REGULATIONS ON EMERGING COMPANIES. INFLUENCED BIO'S HEALTH CARE POLICIES TO REFLECT THE CONCERNS OF SMALL BIOTECHNOLOGY COMPANIES.THE FOOD & AGRICULTURE SECTION 2012 ADVOCACY ACCOMPLISHMENTS: WORKED WITH THE ADMINISTRATION AND CONGRESS TO ADVANCE IMPROVEMENTS TO THE U.S. AND GLOBAL REGULATORY SYSTEMS IN AN EFFORT TO PROVIDE PREDICTABILITY IN REGULATORY DECISIONS. COMPLETED WORK ON THE FIRST AGREEMENT UNDER A VOLUNTARY INDUSTRY MECHANISM ("THE ACCORD") DESIGNED TO PROVIDE A TRANSITION PROCESS FOR PRODUCTS COMING OFF PATENT AND ENTERING THE GENERIC MARKETPLACE. FOSTERED SUPPORT OF NONTRADITIONAL ALLIES THROUGH ONGOING OUTREACH TO ENVIRONMENTAL, ANTI-HUNGER AND CORPORATE ENTITIES, AS WELL AS INTERNATIONAL OFFICIALS, TO ADVANCE UNDERSTANDING OF AGRICULTURE BIOTECHNOLOGY AND THE CHALLENGES RELATED TO UNPREDICTABLE REGULATORY SYSTEMS. SECURED A LETTER TO THE EU COMMISSION RAISING OBJECTIONS TO ITS ANIMAL CLONING REGULATORY POLICIES FROM THE UNITED STATES AND A GROUP OF LIKE-MINDED COUNTRIES. DEFEATED LEGISLATION DESIGNED TO SCARE AND MISINFORM CONSUMERS REGARDING FOOD DERIVED FROM BIOTECHNOLOGY INGREDIENTS.THE INDUSTRIAL & ENVIRONMENTAL SECTION 2012 ADVOCACY ACCOMPLISHMENTS: SUCCESSFULLY ADVOCATED FOR CONGRESS TO PRESERVE THE RENEWABLE FUELS STANDARD. SUCCESSFULLY ADVOCATED FOR THE INTRODUCTION OF SEVERAL FAVORABLE PIECES OF TAX LEGISLATION RELATING TO RENEWABLE CHEMICALS, ALGAE, CELLULOSIC AND OTHER ADVANCED BIOFUELS. WORKED TO SECURE A ROBUST ENERGY TITLE IN FARM BILL REAUTHORIZATION PROPOSALS IN CONGRESS. ADVOCATED REGARDING THE PROPER REGULATORY APPROACH IN THE EMERGING FIELD OF SYNTHETIC BIOLOGY. ADVOCATED FOR THE CERTIFICATION PROCESS FOR THE VOLUNTARY LABELING PROGRAM IN THE U.S. DEPARTMENT OF AGRICULTURES BIOPREFERRED PROGRAM. BIO HELD TWO INDUSTRIAL BIOTECH CONFERENCES IN 2012 THE BIO WORLD CONGRESS ON INDUSTRIAL BIOTECHNOLOGY AND BIOPROCESSING AND THE BIO PACIFIC RIM SUMMIT ON INDUSTRIAL BIOTECHNOLOGY AND BIOENERGY. SERVICESBIO'S SERVICES INCLUDE CONFERENCES AND ACTIVITIES THAT BRING TOGETHER INDUSTRY PARTNERS AND INVESTORS FOR EVENTS RANGING FROM THE BIO INTERNATIONAL CONVENTION TO CONFERENCES FOR BUSINESS DEVELOPMENT EXECUTIVES. THE EVENT ATTRACTED 16,500 ATTENDEES FROM 65 COUNTRIES, AND 49 U.S. STATES, INCLUDING 300 MEMBERS OF THE MEDIA. THE NET INCOME FROM THE CONVENTION SUPPORTS OUR ADVOCACY, PUBLIC OUTREACH, AND OTHER MEMBER SERVICE ACTIVITIES. THE KEY ELEMENTS OF THE BIO INTERNATIONAL CONVENTION ARE EDUCATIONAL PROGRAMMING, EXHIBITION AND THE BIO BUSINESS FORUM, WHICH TAKES PLACE DURING THE CONVENTION, PROVIDED AN OPPORTUNITY FOR BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, ACADEMIC RESEARCH INSTITUTIONS, AND INVESTORS FROM AROUND THE WORLD TO SCHEDULE ONE-ON-ONE MEETINGS AND DISCUSS POTENTIAL BUSINESS OPPORTUNITIES. THE BIO BUSINESS FORUM, WHICH TAKES PLACE DURING THE CONVENTION, PROVIDED AN OPPORTUNITY FOR BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, ACADEMIC RESEARCH INSTITUTIONS, AND INVESTORS FROM AROUND THE WORLD TO SCHEDULE ONE-ON-ONE MEETINGS AND DISCUSS POTENTIAL BUSINESS OPPORTUNITIES; IT HOSTED A RECORD NUMBER OF 25,537 PARTNERING MEETINGS BETWEEN 2,837 COMPANIES AND 150+ COMPANY PRESENTATIONS.CAPITAL FORMATION & BUSINESS DEVELOPMENT - THROUGH A PORTFOLIO OF EVENTS, BIO SUPPORTS THE CAPITAL FORMATION AND BUSINESS DEVELOPMENT NEEDS OF HUNDREDS OF INNOVATIVE COMPANIES THAT FORM THE BASIS OF THE BIOTECHNOLOGY INDUSTRY. THESE PROGRAMS FACILITATE CRITICAL CAPITAL FORMATION AND PARTNERSHIPS, AND PROVIDE PROFESSIONAL SERVICES. THROUGHOUT THE YEAR, BIO HOSTS OR CO-HOSTS NINE NATIONAL AND INTERNATIONAL CONFERENCES THAT PROVIDE VENUES FOR MEMBER AND NON-MEMBER COMPANIES TO PRESENT NEW DATA, MEET AND PARTNER WITH FELLOW BIOTECH COMPANIES, AND ATTRACT FUNDING FROM INVESTORS AND OTHER ORGANIZATIONS. 0 0 0 1 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 180 0 184 1 1 1 1 IN 0 0 0 0 X 116 116 1 0 0 0 1 1 0 1 1 0 0 1 1 1 1 1 1 1 0 0 X JOANNE M DUNCAN 2029629200 1201 MARYLAND AVE SW STE 900 WASHINGTON DC 20024 APEL DANIEL 2.00 X 0 0 0 ATWOOD BRIAN 2.00 X 0 0 0 BEALL ROBERT 2.00 X 0 0 0 BEEMAN DONALD 2.00 X 0 0 0 BEER MARC 2.00 X 0 0 0 BERVEN DOUG 2.00 X 0 0 0 BIENAIME JEAN-JACQUES 2.00 X 0 0 0 BORISY ALEXIS 2.00 X 0 0 0 BORMANN BJ 2.00 X 0 0 0 CLARK IAN 2.00 X 0 0 0 COHEN RON 2.00 X 0 0 0 COLES NANTHONY 2.00 X 0 0 0 COLLINS JAMES 2.00 X 0 0 0 CROOKES STANLEY 2.00 X 0 0 0 CROWLEY JOHN 2.00 X 0 0 0 CUMMINGS DANIEL 2.00 X 0 0 0 DOERFLER DOUGLAS 2.00 X 0 0 0 DUNCAN GREG 2.00 X 0 0 0 DUNSIRE DEBORAH 2.00 X 0 0 0 EGGERT CHARLES 2.00 X 0 0 0 ELLERBUSCH SUSAN 2.00 X 0 0 0 ENO RICHARD 2.00 X 0 0 0 FERGUSON BRUCE 2.00 X 0 0 0 FLINT JERRY 2.00 X 0 0 0 FRITZ CAROLYN 2.00 X 0 0 0 GATTO STEPHEN 2.00 X 0 0 0 GERBERDING JULIE 2.00 X 0 0 0 GERMANO GENO 2.00 X 0 0 0 GIOVANNETTI GLEN 2.00 X 0 0 0 GORMLEY GLENN 2.00 X 0 0 0 GOWEN MAXINE 2.00 X 0 0 0 GREENLEAF PETER 2.00 X 0 0 0 GRUBER PATRICK 2.00 X 0 0 0 GUTTERSON NEAL 2.00 X 0 0 0 HA-NGOC TUAN 2.00 X 0 0 0 HANTSON LUDWIG 2.00 X 0 0 0 HASTINGS PAUL 2.00 X 0 0 0 HATFIELD JEFFERY 2.00 X 0 0 0 HERNDON RUSSELL 2.00 X 0 0 0 HOLTZMAN STEVEN 2.00 X 0 0 0 HOPPENOT HERVE 2.00 X 0 0 0 HOYES JAMES 2.00 X 0 0 0 JOHNSON JOHN 2.00 X 0 0 0 JUNIUS DANIEL 2.00 X 0 0 0 KARSEN PERRY 2.00 X 0 0 0 KING RACHEL 2.00 X 0 0 0 KISS ROBERT 2.00 X 0 0 0 KOENIG SCOTT 2.00 X 0 0 0 KOSACZ BARBARA 2.00 X 0 0 0 KREMER MATTHIAS 2.00 X 0 0 0 LEAHY EMER 2.00 X 0 0 0 LEFF JONATHAN 2.00 X 0 0 0 LEONARD JOHN 2.00 X 0 0 0 LEIDEN JEFFERY 2.00 X 0 0 0 LESCHLY NICK 2.00 X 0 0 0 LEVINE JAMES 2.00 X 0 0 0 LUNDBERG JAN 2.00 X 0 0 0 MANUSO JAMES 2.00 X 0 0 0 MARAGANORE JOHN 2.00 X 0 0 0 MATHERS EDWARD 2.00 X 0 0 0 MATHERS THOMAS 2.00 X 0 0 0 MCCAULEY GORDON 2.00 X 0 0 0 MCHUGH JULIE 2.00 X 0 0 0 MEDFORD RUSSELL 2.00 X 0 0 0 MEEKER DAVID 2.00 X 0 0 0 MENLEIN JOHN 2.00 X 0 0 0 MENTO STEVEN 2.00 X 0 0 0 MILANO VINCENT 2.00 X 0 0 0 MILLIGAN JOHN 2.00 X 0 0 0 MOCH KENNETH 2.00 X 0 0 0 MONROE ADAM 2.00 X 0 0 0 MORRIS ARLENE 2.00 X 0 0 0 NARACHI MICHAEL 2.00 X 0 0 0 NICOLAIDES NICHOLAS 2.00 X 0 0 0 NICOLS JOHN 2.00 X 0 0 0 ORWIN JOHN 2.00 X 0 0 0 OSTROVE JEFFERY 2.00 X 0 0 0 PEACOCK JONATHON 2.00 X 0 0 0 PELTZ STUART 2.00 X 0 0 0 PERKINS ADELENE 2.00 X 0 0 0 PETERSON KRISTINE 2.00 X 0 0 0 POPS RICHARD 2.00 X 0 0 0 PREUSS DAPHINE 2.00 X 0 0 0 PRUZANSKI MARK 2.00 X 0 0 0 PYOTT DAVID 2.00 X 0 0 0 READNOUR ROBIN 2.00 X 0 0 0 ROBIN HOWARD 2.00 X 0 0 0 RODELL TIMOTHY 2.00 X 0 0 0 RYDER STEVEN 2.00 X 0 0 0 SACCHETTI RAYMOND 2.00 X 0 0 0 SANDS ARTHUR 2.00 X 0 0 0 SCHENKEIN DAVID 2.00 X 0 0 0 SCHMIDT RALF-MICHAEL 2.00 X 0 0 0 SHURDUT BRADLEY 2.00 X 0 0 0 SIEGEL JAY 2.00 X 0 0 0 SKALETSKY MARK 2.00 X X 0 0 0 SLAOUI MONCEF 2.00 X 0 0 0 STANDLEE CHRISTOPHER 2.00 X 0 0 0 STEINER GERALD 2.00 X 0 0 0 STOTISH RONALD 2.00 X 0 0 0 SULLIVAN EDDIE 2.00 X 0 0 0 TANDA STEPHAN 2.00 X 0 0 0 TASSE DANIEL 2.00 X 0 0 0 THAKRAR ATUL 2.00 X 0 0 0 TUTTLE STEVEN 2.00 X 0 0 0 VAN BOKKENLEN GIL 2.00 X 0 0 0 VAN WART HAROLD 2.00 X 0 0 0 VERBRUGGEN MARC 2.00 X 0 0 0 WALBERT TIMOTHY 2.00 X 0 0 0 WATKINS H THOMAS 2.00 X X 0 0 0 WELLS BARBARA 2.00 X 0 0 0 WOLFSON JONATHAN 2.00 X 0 0 0 WONG MARK 2.00 X 0 0 0 XANTHOPOULO KLEANTHIS 2.00 X 0 0 0 ZAKES BRADFORD 2.00 X 0 0 0 ZULLO JILL 2.00 X 0 0 0 GREENWOOD JAMES 40.00 X 1575000 0 95581 JOANNE DUNCAN 40.00 X 317125 0 52194 WHITAKER A SCOTT 40.00 X 761738 0 50953 BITTENBENDER FREDERICK 40.00 X 334555 0 52059 DAMOND JOSEPH 40.00 X 337255 0 51614 DILENGE THOMAS 40.00 X 526852 0 51874 ENRIGHT CATHLEEN 40.00 X 260469 0 46469 EISENBERG ALAN 40.00 X 549590 0 52894 DEL MONTE BRENT 40.00 X 488567 0 41659 ERICKSON BRENT 40.00 X 406730 0 49540 FINAN AMY 40.00 X 374693 0 42325 JOSEPH JEFFREY 40.00 X 298608 0 19806 LISAIUS KENNETH 40.00 X 241376 0 43200 LYCETT ROBERTA 40.00 X 358419 0 47080 RADCLIFFE SARA 40.00 X 468366 0 41814 DENNIS SANDRA 40.00 X 294971 0 44000 SAUER HANSJORG 40.00 X 291501 0 42024 MCHUGH PETER 40.00 X 266417 0 43463 FEISEE LILA 40.00 X 264687 0 49474 BASU ABHIJIT 40.00 X 242409 0 39302 8659328 0 957325 73 0 1 0 FREEMAN COMPANIES 1600 VICEROY SUITE 100 DALLAS TX 75247 GENERAL CONTRACTOR: CONV/CONFERENCES 1600074 PROJECTION INC PO BOX 890472 CHARLOTTE NC 28289 VIDEO SERVICES: CONV/CONFERENCES 759408 FIXATION MARKETING 4340 EAST-WEST HWY SUITE 200 BETHESDA MD 208144411 MARKETING: INTN'L CONVENTION 758897 LEVY RESTAURANTS FOOD SERVICE 415 SUMMER STREET BOSTON MA 02210 CATERING SERVICES: INTN'L CONV 702429 RHODE PLANNING & MGMT SOLUTIONS 42 LADD ST SUITE 302 EAST GREENWICH RI 02818 TRANSPORTATION SERVICES: INTN'L CONV 666948 79 CONFERENCE/MEETING REVENUE 541800 32875142 32577675 297467 MEMBERSHIP DUES 900099 22832307 22832307 BUSINESS SOLUTIONS 900099 4133993 4133993 PUBLICATION ADVERTISING 541800 41569 144 41425 59883011 1579991 1579991 35049246 34228784 820462 820462 820462 MISCELLANEOUS REVENUE 900099 3959 3959 3959 62287423 55414085 338892 6534446 232395 8038405 15126484 1211061 1585878 1113487 532270 57835 2778505 361314 5653221 238553 1663338 738577 4026592 1226986 16970648 6123 1441546 1010804 100708 OUTREACH 388057 BAD DEBT EXPENSE 268187 TAXES PAID 82691 EDUCATION 52153 21520 64927338 4459681 2528659 2602547 3117733 2383665 2423170 10061437 6767357 4032862 3294080 52118530 53510015 260352 181265 65857637 65054922 8591779 9709497 13043071 10570025 6142417 5871571 27777267 26151093 X 38080370 38903829 38080370 38903829 65857637 65054922 X -2639915 3231009 232365 X 0 1 X 1 0 0 0 1 22832307 7540000 21386 7561386 7535000 26386 5880250 3139071 2741179 1809191 1628809 180382 2371996 1999477 372519 3294080 CAPITAL LEASE OBLIGATION 133842 DEFERRED RENT 5737729 5871571 66153660 3231009 996542 4227551 61926109 361314 361314 62287423 65330201 764177 764177 64566024 361314 361314 64927338 PART XI, LINE 2D - OTHER ADJUSTMENTS: CBI 41,340. CBI LOBBYING FUND 433,424. FOOD & AG INITIATIVES REVENUE 209,301. FOOD & AG LEGAL FUND 22,762. SUSTAINABLE TASK FORCE 9,715. MEDICARE EXPENSES 280,000. PART XII, LINE 2D - OTHER ADJUSTMENTS: FOOD & AG INITIATIVES EXPENSES 14,827. CBI LOBBYING FUND 469,350. MEDICARE EXPENSES 280,000. EUROPE 0 1 PROGRAM SERVICES CONFERENCE 147971 SOUTH ASIA 0 3 PROGRAM SERVICES CONFERENCE 225217 EAST ASIA AND THE PACIFIC 0 2 PROGRAM SERVICES CONFERENCE 1633470 NORTH AMERICA 0 0 PROGRAM SERVICES CONFERENCE 213144 0 6 0 0 0 6 2219802 0 2219802 0 0 0 0 0 0 0 ALLIANCE FOR A STRONGER FDA PO BOX 7508 SILVER SPRING MD 209077508 204669553 25000 PROGRAM ACTIVITIES NEHI ONE BROADWAY 15TH FLOOR CAMBRIDGE MA 21420 010624865 25000 PROGRAM ACTIVITIES WOMEN IN BIO INC PO BOX 34043 BETHESDA MD 20827 030458239 8000 PROGRAM ACTIVITIES PARKINSON'S ACTION NETWORK 1025 VERMONT AVE SUITE 1120 WASHINGTON DC 20025 943172675 501(C)3 5000 SPONSORSHIP AMERICAN CANCER SOCIETY 1599 CLIFTON ROAD NE ATLANTA GA 30329 131788491 501(C)3 5000 SPONSORSHIP COLON CANCER ALLIANCE INC 1025 VERMONT AVE NW SUITE 1066 WASHINGTON DC 20005 860947831 6000 SPONSHORSHIP SOUTH CAROLINA BIOTECH ASSN 411 UNIVERSITY RIDGE SUITE A GREENVILLE NC 29601 200813951 501(C)3 12400 SPONSORSHIP CHILDREN'S CAUSE FOR CANCER 750 FIRST ST NE 7TH FLOOR WASHINGTON DC 20002 113485631 6500 SPONSORSHIP ALS ASSOCIATION 1275 K ST NW SUITE 1050 WASHINGTON DC 20005 133271855 5000 SPONSORSHIP ALLIANCE FOR AGING RESEARCH 750 17TH ST NW SUITE 1100 WASHINGTON DC 20006 541379174 5000 SPONSORSHIP FRIENDS OF CANCER RESEARCH 1800 M ST NW SUITE 1050 WASHINGTON DC 20036 521983273 5000 SPONSORSHIP NATIONAL MULTIPLE SCIEROSIS 1800 M STREET NW S750 SOUTH WASHINGTON DC 20036 530237585 501(C)3 5000 SPONSORSHIP MICHAEL J FOX FOUNDATION 498 SEVENTH AVENUE 18TH FLOOR NEW YORK NY 10018 134041945 501(C)3 5000 SPONSORSHIP MILKEN INSTITUTE 1250 FOURTH STREET 2ND FLOOR SANTA MONICA CA 90401 954240775 25000 SPONSORSHIP THE CONGRESSIONAL HUNGER CENTER 400 N CAPITOL ST NW SG100 WASHINGTON DC 20001 521842738 10000 SPONSORSHIP WEST VIRGINIA BIOSCIENCE 425 3RD ST SW SUITE 950 SUITE 350 HUNTINGTON WV 25718 271343598 7300 SPONSORSHIP TEXAS HEALTHCARE 815 BRAZOS ST SUITE 310 AUSTIN TX 78701 760501034 5000 SPONSORSHIP MID-ATLANTIC BIO 1551 EASTLAKE AVE E MCCLEAN VA 22102 550899397 10000 SPONSORSHIP 5 13 X X X 1 1 X X X X 0 1 0 GREENWOOD JAMES 1000000 0 575000 0 0 0 26232 0 69349 0 1670581 0 0 0 JOANNE DUNCAN 301375 0 15750 0 0 0 25120 0 27074 0 369319 0 0 0 WHITAKER A SCOTT 570263 0 191475 0 0 0 26232 0 24721 0 812691 0 0 0 BITTENBENDER FREDERICK 324555 0 10000 0 0 0 22482 0 29577 0 386614 0 0 0 DAMOND JOSEPH 312842 0 24413 0 0 0 25417 0 26197 0 388869 0 0 0 DILENGE THOMAS 394419 0 132433 0 0 0 26232 0 25642 0 578726 0 0 0 ENRIGHT CATHLEEN 251719 0 8750 0 0 0 24686 0 21783 0 306938 0 0 0 EISENBERG ALAN 411442 0 138148 0 0 0 26232 0 26662 0 602484 0 0 0 DEL MONTE BRENT 365758 0 122809 0 0 0 26232 0 15427 0 530226 0 0 0 ERICKSON BRENT 336730 0 70000 0 0 0 26232 0 23308 0 456270 0 0 0 FINAN AMY 280508 0 94185 0 0 0 26232 0 16093 0 417018 0 0 0 JOSEPH JEFFREY 200716 0 97892 0 0 0 500 0 19306 0 318414 0 0 0 LISAIUS KENNETH 220376 0 21000 0 0 0 22791 0 20409 0 284576 0 0 0 LYCETT ROBERTA 274321 0 84098 0 0 0 26232 0 20848 0 405499 0 0 0 RADCLIFFE SARA 350635 0 117731 0 0 0 26232 0 15582 0 510180 0 0 0 DENNIS SANDRA 275971 0 19000 0 0 0 26232 0 17768 0 338971 0 0 0 SAUER HANSJORG 259501 0 32000 0 0 0 24256 0 17768 0 333525 0 0 0 MCHUGH PETER 245417 0 21000 0 0 0 25697 0 17766 0 309880 0 0 0 FEISEE LILA 229507 0 35180 0 0 0 24199 0 25275 0 314161 0 0 0 BASU ABHIJIT 196409 0 46000 0 0 0 21609 0 17693 0 281711 0 0 0 PART I, LINE 1A JAMES GREENWOOD - FIRST CLASS TRAVEL - $1,281 - TRAVEL FOR COMPANIONS - $3,763 ALAN EISENBERG - FIRST CLASS TRAVEL - $519 - HEALTH/SOCIAL CLUB DUES - $810 CATHLEEN ENRIGHT - FIRST CLASS TRAVEL - $569 JOSEPH DAMOND - FIRST CLASS TRAVEL - $478 THE ABOVE ITEMS WERE NOT INCLUDED IN THE TAXABLE INCOME OF THE INDIVIDUAL. PART I, LINE 4B . JAMES GREENWOOD 457(F) PLAN NO PAYMENTS IN CURRENT YEAR FORM 990, PART VI, SECTION A, LINE 1 THE BOARD OF DIRECTORS SHALL DESIGNATE, BY RESOLUTION AND WITH A QUORUM PRESENT, NOT MORE THAN NINETEEN (19) DIRECTORS OF THE BOARD TO ACT AS AN EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE SHALL CONSIST OF THE SEVEN (7) ELECTED OFFICERS OF THE ORGANIZATION (AS DEFINED IN ARTICLE VIII); THE IMMEDIATE PAST CHAIR OF THE ORGANIZATION; THE VICE CHAIRS OF EACH SECTION'S GOVERNING BOARD; AND THE BALANCE BEING AT-LARGE DIRECTORS FROM THE FULL BOARD. IF THE IMMEDIATE PAST CHAIR IS NO LONGER ELIGIBLE TO SERVE ON THE FULL BOARD, AN ADDITIONAL AT-LARGE DIRECTOR FROM THE FULL BOARD SHALL BE SELECTED FOR THE EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE SHALL HAVE, AND BE AUTHORIZED TO EXERCISE, ALL POWERS OF THE FULL BOARD, EXCEPT: (A) THE POWER TO ELECT OR REMOVE ELECTED OFFICERS OR DIRECTORS, TO CHANGE THE SIZE OF THE BOARD, TO CHANGE ELIGIBILITY, QUALIFICATIONS OR RIGHTS OF MEMBERSHIP, TO APPROVE THE FINANCIAL BUDGET FOR THE ORGANIZATION, OR TO MAKE DETERMINATIONS AS TO DIRECTOR AND OFFICER COMPENSATION, WHERE APPLICABLE; AND (B) THE POWER TO AMEND THE ARTICLES OF INCORPORATION OR THE BYLAWS OF THE ORGANIZATION. FORM 990, PART VI, SECTION A, LINE 2 BASED ON RESPONSES TO A SURVEY DISTRIBUTED TO EACH MEMBER OF BIO'S BOARD OF DIRECTORS, TWO DIRECTORS -- VINCENT MILANO AND JOHN MENDLEIN -- DISCLOSED THAT IN 2012 EACH HAD A BUSINESS RELATIONSHIP AS DEFINED BY THE FORM 990 INSTRUCTIONS. FORM 990, PART VI, SECTION A, LINE 6 THE MEMBERS OF THE ORGANIZATION SHALL BE DIVIDED INTO FOUR CLASSES; CORE MEMBERS, ASSOCIATE MEMBERS, AFFILIATE MEMBERS, AND CENTER MEMBERS, DEFINED AS FOLLOWS: (A) CORE MEMBERS. ANY CORPORATION, PARTNERSHIP, ASSOCIATION, OR OTHER ENTITY ORGANIZED FOR PROFIT, A SUBSTANTIAL PERCENTAGE OF WHOSE BUSINESS ACTIVITIES INVOLVE BIOTECHNOLOGY, GENOMICS, BIOINFORMATICS OR RELATED NEW TECHNOLOGIES, IS ELIGIBLE FOR MEMBERSHIP. CORE MEMBERS ARE THOSE ENTITIES THAT UTILIZE BIOTECHNOLOGY, GENOMICS, BIOINFORMATICS OR OTHER RELATED NEW TECHNOLOGIES IN RESEARCH, DEVELOPMENT, TESTING, MANUFACTURING, OR SALES OF PRODUCT OR INFORMATION, AS WELL AS OTHER FIRMS THE BOARD SO CHARACTERIZES AND PLACES IN THIS CATEGORY. CORE MEMBERS SHALL BE GROUPED IN THE FOLLOWING SUBCATEGORIES: (I) EMERGING COMPANIES, WHICH ARE FIRMS THAT EMPLOY LESS THAN 350 PERSONS AND THAT DO NOT HAVE A THERAPEUTIC OR DIAGNOSTIC PRODUCT APPROVED FOR SALE IN THE U.S. MARKET; (II) ESTABLISHED FIRMS, WHICH ARE THOSE FIRMS THAT EMPLOY 350 OR MORE PERSONS OR THAT HAVE A THERAPEUTIC OR DIAGNOSTIC PRODUCT APPROVED FOR SALE IN THE U.S. MARKET; AND (III) LARGE FIRMS, WHICH ARE ESTABLISHED FIRMS THAT HAVE ANNUAL WORLDWIDE SALES OF BIOTECHNOLOGY PRODUCTS IN EXCESS OF $1.5 BILLION; AND (IV) NON-DOMESTIC COMPANIES, WHICH ARE CORE MEMBERS WITHOUT SIGNIFICANT OPERATIONS IN THE UNITED STATES OR SIGNIFICANT COLLABORATIONS WITH A U.S. ENTITY. (B) ASSOCIATE MEMBERS. ANY CORPORATION, PARTNERSHIP, ASSOCIATION, OR OTHER ENTITY ORGANIZED FOR PROFIT, A SUBSTANTIAL PORTION OF WHOSE ACTIVITIES INVOLVE PROVIDING SERVICES OR PRODUCTS OF BENEFIT TO COMPANIES WHOSE PRINCIPAL BUSINESS IS BIOTECHNOLOGY, IS ELIGIBLE FOR ASSOCIATE MEMBERSHIP. ASSOCIATE MEMBERS ARE THOSE COMMERCIAL ENTITIES WHICH DO NOT NECESSARILY UTILIZE BIOTECHNOLOGY; E.G. TECHNICAL SUPPORT, EQUIPMENT, CONSTRUCTION, ACCOUNTING, AND LAW FIRMS THAT SERVICE THE BIOTECHNOLOGY INDUSTRY, AS WELL AS OTHER FIRMS THAT THE BOARD CHARACTERIZES AND PLACES IN THIS CATEGORY. (C) AFFILIATE MEMBERS. ANY GOVERNMENTAL OR NONPROFIT ENTITY OR COUNTRY, STATE OR REGIONAL INDUSTRY, TRADE OR PROFESSIONAL ASSOCIATION WITH AN INTEREST IN, OR A MANDATE TO PROMOTE THE DEVELOPMENT OF, BIOTECHNOLOGY IS ELIGIBLE FOR AFFILIATE MEMBERSHIP. THERE SHALL BE NO SIZE TESTS APPLIED TO AFFILIATE MEMBER APPLICANTS. (D) CENTER MEMBERS. ANY INSTITUTION, NOT GENERALLY ELIGIBLE FOR CORE MEMBERSHIP THAT IS SPONSORED BY A STATE, REGION, OR ACADEMIC INSTITUTION AND WORKS IN SUPPORT OF COMMERCIAL BIOTECHNOLOGY MAY BE ELIGIBLE FOR CONSIDERATION AS A CENTER MEMBER. FORM 990, PART VI, SECTION A, LINE 7A AT ALL MEMBERSHIP MEETINGS OF THE ORGANIZATION, EACH CURRENT MEMBER SHALL HAVE ONE (1) VOTE AND MAY TAKE PART IN THE VOTING IN PERSON OR BY PROXY. FOR EACH SECTION IN WHICH THE MEMBER PARTICIPATES, EACH MEMBER SHALL HAVE THE RIGHT TO VOTE ON THE ELECTION OF DIRECTORS FOR THE SECTION GOVERNING BOARD, BUT SHALL HAVE NO OTHER VOTING RIGHTS EXCEPT ON MATTERS BROUGHT TO THE MEMBERSHIP BY ANY SUCH GOVERNING BOARD OR THE ORGANIZATION'S BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 AND RELATED SCHEDULES ARE PREPARED BY THE ORGANIZATION'S CERTIFIED PUBLIC ACCOUNTANTS UNDER THE GUIDANCE OF THE CFO. THE CFO AND THE CONTROLLER THOROUGHLY REVIEW ALL CALCULATIONS AND SCHEDULES TO CONFIRM THEY REFLECT THE ACTUAL FINANCIAL RESULTS OF THE ORGANIZATION. THE COMPLETE FORM 990 IS THEN REVIEWED INTERNALLY BY THE CEO, COO, CFO, AND CONTROLLER IN CONSULTATION WITH LEGAL COUNSEL AND, AS APPROPRIATE, FURTHER CONSULTATION WITH THE ORGANIZATION'S CERTIFIED PUBLIC ACCOUNTANTS. FINALLY, THE FORM 990 IS PROVIDED TO THE CHAIRMAN OF THE BOARD AND BIO EXECUTIVE COMMITTEE MEMBERS FOR THEIR REVIEW, QUESTIONS AND/OR COMMENTS, AND THEN SENT TO THE BIO EXECUTIVE COMMITTEE MEMBERS FOR THEIR REVIEW, QUESTIONS AND/OR COMMENTS AS WELL. ALL REVIEWS ARE COMPLETED BEFORE THE FORM IS FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C BIO TAKES SEVERAL STEPS TO ADDRESS COMPLIANCE BY EMPLOYEES AND DIRECTORS WITH ITS CONFLICTS OF INTEREST POLICY. BIO TRAINS ALL NEW EMPLOYEES AND DIRECTORS ON VARIOUS ASPECTS OF BIOS COMPLIANCE PROGRAM, INCLUDING CONFLICTS OF INTEREST, AND BIOS WRITTEN CONFLICTS OF INTEREST POLICY REQUIRES ALL EMPLOYEES TO DISCLOSE ANY OUTSIDE PERSONAL BUSINESS INTERESTS TO THEIR SUPERVISOR. BIO'S GENERAL COUNSEL REGULARLY ADVISES BIO'S EXECUTIVES AND SUPERVISORS ON SUCH MATTERS. BIO ALSO CONTRACTS WITH AN INDEPENDENT ORGANIZATION TO PROVIDE EMPLOYEES AND OTHERS WITH THE ABILITY TO FILE ANONYMOUS REPORTS CONCERNING THE VIOLATION OF ANY LAWS OR BIO POLICIES, INCLUDING ALLEGATIONS OF POTENTIAL CONFLICTS OF INTEREST, AND BIO HAS A PROCESS IN PLACE TO FOLLOW UP ON ANY SUCH COMPLAINTS IN A TIMELY AND THOROUGH MANNER. FURTHER, BIO UNDERTAKES A QUESTIONNAIRE SENT TO EACH MEMBER OF ITS BOARD OF DIRECTORS SEEKING DISCLOSURE OF ANY POTENTIAL CONFLICTS OF INTERESTS THEY MAY HAVE, OR THEIR FAMILY MEMBERS MAY HAVE, ASSOCIATED WITH BUSINESSES OR ORGANIZATIONS THAT DO BUSINESS WITH BIO. POTENTIAL CONFLICTS ARE MONITORED AND REVIEWED AT THE MANAGEMENT AND SENIOR MANAGEMENT LEVEL OF THE ORGANIZATION, AND DEPENDING ON THE CONFLICT, DETERMINATIONS MAY BE MADE AT THE BOARD OR SENIOR MANAGEMENT LEVEL. A CONFLICT AT THE BOARD LEVEL WILL NORMALLY RESULT IN RECUSAL OF THE INDIVIDUAL FROM PARTICIPATION OR ACTIVITIES WITH RESPECT TO THE RELEVANT SUBJECT MATTER. AT THE STAFF LEVEL, THE APPLICABLE BIO SUPERVISOR IS INFORMED OF THE POTENTIAL CONFLICT AND IS REQUIRED TO TAKE ALL APPROPRIATE STEPS TO ENSURE THAT THE INDIVIDUAL DOES NOT PARTICIPATE IN, OR RECEIVE CONFIDENTIAL INFORMATION RELATING TO, ANY BIO ACTIVITY RELATED TO THE SUBJECT MATTER OF THE CONFLICT, UP TO AND INCLUDING, WHERE APPROPRIATE, TERMINATION OF SUCH EMPLOYEE. FORM 990, PART VI, SECTION B, LINE 15A THE PERFORMANCE AND COMPENSATION OF THE PRESIDENT AND CEO OF BIO FOR 2012 WAS REVIEWED AND DETERMINED IN A PROCESS THAT WAS LED BY THE CHAIRMAN OF THE BOARD AND INVOLVED THE FULL EXECUTIVE COMMITTEE OF THE BOARD. THE BIO EXECUTIVE COMMITTEE, WHICH IS COMPRISED OF INDEPENDENT BIO BOARD MEMBERS, LEADS AND UNDERTAKES THIS ANNUAL PROCESS. IF NEEDED IN CARRYING OUT THIS PROCESS, THE MEMBERS OF THE EXECUTIVE COMMITTEE CAN BE ASSISTED AND COUNSELED BY BOTH INDEPENDENT OUTSIDE LEGAL COUNSEL WHO IS AN EXPERT IN THIS AREA OF THE LAW, AND AN INDEPENDENT OUTSIDE CONSULTANT THAT PROVIDES BENCHMARKING SERVICES AND INFORMATION ON EXECUTIVE COMPENSATION ISSUES. THE UNDERLYING EXECUTIVE EMPLOYMENT AGREEMENT WAS REVISED AND EXTENDED IN 2011, IN CONSULTATION WITH EXTERNAL INDEPENDENT LEGAL AND COMPENSATION CONSULTANTS AND WITH THE FULL BOARD OF DIRECTORS, AND WITH FINAL APPROVAL BY THE EXECUTIVE COMMITTEE OF THE BOARD. BASED ON THE EXECUTIVE COMMITTEE'S EVALUATION OF THE PRESIDENT AND CEO'S PERFORMANCE FOR 2012, THE COMMITTEE DETERMINED THE APPROPRIATE AMOUNT FOR THE DISCRETIONARY COMPONENT OF HIS COMPENSATION FOR THAT YEAR, IN ACCORDANCE WITH PROVISIONS OF THE EXECUTIVE AGREEMENT. FORM 990, PART VI, SECTION B, LINE 15B: DECISIONS REGARDING THE COMPENSATION FOR OFFICERS AND KEY EMPLOYEES OF THE ORGANIZATION ARE NEGOTIATED INDIVIDUALLY AND ARE PERFORMANCE-BASED, IN ACCORDANCE WITH AN ANNUAL WRITTEN EVALUATION PROCESS THAT HAS BEEN ESTABLISHED FOR ALL EMPLOYEES OF THE ORGANIZATION. THE CHIEF OPERATING OFFICER LEADS AND UNDERTAKES THIS PROCESS, IN COORDINATION WITH THE PRESIDENT & CEO. AN INDEPENDENT CONSULTANT PROVIDES COMPARATIVE BENCHMARKING SERVICES FOR SENIOR MANAGEMENT POSITIONS, AND OTHER INFORMATION ON COMPENSATION ISSUES, TRENDS, POLICIES, AND BEST PRACTICES FOR USE BY THE ORGANIZATION. THE ORGANIZATION ALSO HAS AN ESTABLISHED COMPENSATION POLICY FOR ALL OF ITS EMPLOYEES, WHICH SETS FORTH THE GENERAL PARAMETERS GOVERNING BIO'S COMPENSATION PRACTICES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION DOES NOT MAKE ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC. CHANGES IN NET ASSETS OR FUND BALANCES: FORM 990, PART XI, LINE 9: CBI REVENUE 41,340. CBI LOBBYING FUND REVENUE 433,424. FOOD & AG INITIATIVES REVENUE 209,301. FOOD & AG INITIATIVES EXPENSES -14,827. FOOD & AG LEGAL FUND 22,762. CBI LOBBYING FUND EXPENSE -469,350. SUSTAINABLE TASK FORCE 9,715.